Kangmei Pharmaceuticals 7 executives left the collective, this year has nearly 100 pharmaceutical executives out!

Guide: Directors removed!Ping An Health director removed! On May 18, Ping An Doctor issued a notice that the board of directors had decided to remove MrWang Tao from his post as chairman, executive director and chief executive officer for personal reasonsOn the same day, the Board appointed MrFang Weihao as Executive Director, Interim Chairman of the Board and Chief Executive OfficerThe appointment and removal notice took effect on Friday (May 15)it is understood that before joining Ping An, Wang Tao was the chief technology officer of Jinshan Technology, senior vice president of Alibaba Group, chairman of Ali Software, has been praised by the industry as "the father of China's software operation applications." Successor Fang Weihao, 47, Ph.Din Applied Economics, Xi'an Jiaotong University, is currently co-chairman and CEO of Ping An Health Insurance Technology, chairman and CEO of Ping An LeasingFang Weihao joined Ping An Group in August 2012 and participated in the creation of Ping An Leasing Company, which has led the company to achieve steady growth in asset growth and become the first echelon of the industry by laying out vertical business growth areas such as autofinance, health testing center and micro-leasingEspecially in the field of medical and health care, actively implement Ping An Group's "medical health ecosystem" strategy, the establishment of Ping An Health (testing) center, the first in the country imaging diagnosis, medical examination and precision examination of the "Trinity" of the third-party medical services, and actively promote the national graded diagnosis and treatment policy smoothly landingthe specific reasons for Wang Tao's dismissal, the industry speculation, but Ping An good doctor has previously been caught in the "plagiarism door" caused public concernMa Jianfei, chief executive of artificial intelligence company Xueyang Technology, posted a lengthy post on a personally certified microblog accusing Ping An of unfair competition and violating trade secretsOn May 15, weChat Public Number "Anton Alert Center" of the Anton Alert Watch published an article announcing that Xueyang Technology had filed a complaint and evidence material with the Intellectual Property Court, and filed a lawsuit against Ping An Health Internet Co., Ltdand Ping An Health Medical Technology Co., Ltd., which has now been filed, with the screenshot showing the application date of May 13, 2020, number 1053679in recent days, seven senior executives of Kangmei Pharmaceuticals have left, and several well-known pharmaceutical companies have announced that executives have leftThese include Jiang Guoliang, the supervisor of Boya Biopharmaceutical son-in-command, Hu Weibing, deputy general manager of Shanghai Laishi, Yang Siwei, director and general manager of Haixiang Pharmaceuticals, and Li Jing, director of Tianjin Tian PharmaceuticalS, the most notable of which is the collective departure of seven executives from Kangmei Pharmaceuticals On May 14, the CSRC formally decided to punish Kangmei Pharmaceuticals for inflating huge revenues, including six of the main responsible persons who took 10-year-old securities market ban measures, including the company's chairman, general manager Ma Xingtian, vice chairman, executive vice president Xu Dongxuan, the company's deputy general manager Lin Guoxiong, the company's finance director Zhuang Yiqing and the company's deputy general manager Wen Shaosheng May 15, Kangmei Pharmaceuticals issued a notice that it received the resignation report of the above five relevant personnel and effective, the resignation of the above personnel will not lead to the company's board of directors below the required minimum number of people, will not affect the normal operation of the board of directors In addition, there are Luo Jiaqian, who resigned as chairman of the company's supervisory board for personal reasons, and Ma Huanzhou, who resigned as the company's supervisory board The penalty decision resulted in the collective departure of seven executives, and the decision to ban access to the market was a fear that the industry would not be mixed up this year, nearly 100 pharmaceutical executives have left! since May, there have been the departure of senior executives of pharmaceutical companies, many of which are well-known pharmaceutical company executive positions change frequently! May 17, Boya Bio issued a notice that the Supervisory Board received a written "resignation report" submitted by Jiang Guoliang, the company's staff representative Jiang Guoliang will no longer hold any positions in the company after his resignation, the company's 2019 disclosure results show that Jiang Guoliang pre-tax compensation of 375,000 yuan, holding 398,629 shares of the company May 16, Shanghai Laishi Blood Products Co., Ltd announced that the board of directors recently received the resignation report of the company's deputy general manager, Mr Hu Weibing Mr Hu Weibing applied to resign as deputy general manager of the company due to changes in his position, and he will remain in the company after his resignation, and will serve as the staff representative supervisor of the company's fifth supervisory board As of the date of disclosure of this announcement, Mr Hu Weibing holds 720,000 shares of the Company May 16, Zhejiang Haixiang Pharmaceutical Co., Ltd announced that Mr Yang Siwei for personal reasons, applied to resign from the company's director, general manager and other positions After resigning, he will no longer hold any position in the Company and its subsidiaries As of the date of this announcement, Mr Yang Siwei holds 4.8578 million shares of the Company May 15, Tianjin Tian Pharmaceutical Co., Ltd announced that due to changes in work, Ms Li Jing applied to resign as a director of the company's 7th Board of Directors and a member of the Strategy Committee Ms Li Jing will no longer hold any positions in the company after her resignation May 13, Huaren Pharmaceuticals announced that Executive Director Shen Hongze has applied to resign as Ceo of the 6th Board of Directors for personal reasons and will not continue to hold other positions after resigning, while Vice President Li Xiaoli has applied to resign as Vice President of the 6th Board of Directors for personal reasons and will not continue to hold other positions after resigning It is understood that in 2019, Huaren Pharmaceuticalannounc announced the resignation of the CEO, vice president of the number of 4 people, in addition to the chairman of the board of directors from Zhou Xijian to Yang Yidong May 11, Zhejiang Zoli Pharmaceutical Co., Ltd also announced that the company's sixth board of directors independent director Yuan Bin resigned from his post, no longer hold any positions in the company In March, Zoe Pharmaceuticals also announced the departure of the director, independent director Chen Zhimin resigned from the company's sixth board of directors for personal reasons
May 6, Fosun Pharmaceuticals announced that for personal reasons Hequn Yin applied to the company's board of directors to resign as senior vice president, Hequn Yin resigned after the company's senior vice president It is reported that Dai Kuncai was appointed vice president of Fosun Pharmaceuticals, less than three months into his post, April 17, Fosun Pharmaceutical Vice President Dai Kun resigned for personal reasons Dai Kun's resignation comes just over half a month after Hequn Yin, Fosun's senior vice president of medicine, also resigned May 6, Yuanhe Tong Pharmaceuticals announced that the Company's Board of Directors received a resignation report from Mr Shen Hongliang, a director, who resigned as a director for personal reasons, effective April 18, 2020, and will not hold any other positions in the Company after his resignation May 6, Tongji Pharmaceuticals announced that the Company's Supervisory Board received a resignation report from Mr Liu Hongbin, Chairman of the Supervisory Board, on April 30, 2020, who for personal reasons requested to resign as Chairman of the Board of Supervisors of the Company and no longer hold other positions in the Company after his resignation May 6, Hongbo Gene announced that the Board of Directors of the Company received a resignation report from The Director, Mr Chen Yunfeng, on April 30, 2020, who resigned as director for personal reasons and continued to serve as General Manager of the subsidiary, Tynott according to incomplete statistics, , more than 80 executives have left the pharmaceutical industry so far this year In April 2020 alone, 18 pharmaceutical executives offered to resign These include Kong Tai, President of Ted Pharmaceuticals, Wang Xuehai, Chairman of Renfu Pharmaceuticals, Liu Tianzhi, Director of Jiangzhong Pharmaceuticals, Yu Qi, Deputy General Manager of Northeast Pharmaceuticals, Wang Haoxuan, Tian Wei, Assistant President of Dong Agu, and Chen Wei, Chairman of Borui Pharmaceuticals a series of reform measures such as "two-vote system", with quantity procurement, and dynamic adjustment of medical insurance catalogue, the pharmaceutical market environment has undergone great changes Under pressure such as compliance, more and more pharmaceutical companies have begun to adjust their marketing operations, shrink research and development lines, and even lay off workers to withstand the cold winter of industry development the industry generally believe that in the domestic pharmaceutical field of the New Deal, the pharmaceutical companies continue to adjust personnel and strategic deployment, is also helpless As more New Deals come into force, more and more companies will join the adjustment team Responsible Editor: Lu Lujun
related labels: national , Kangmei Pharmaceuticals 0
0